Skip to main content

ASCVD

2
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Daewon Pharma
Daewon PharmaKorea - Hwaseong
1 program
1
Combination therapyPhase 41 trial
Active Trials
NCT06767774Recruiting2,000Est. Jan 2030
Sandoz
SandozAustria - Kundl
1 program
1
Inclisiran SodiumPhase 3RNA Therapeutic1 trial
Active Trials
NCT03814187Completed3,275Est. Feb 2023
Amgen
AmgenTHOUSAND OAKS, CA
1 program
Care Champion InterventionN/A1 trial
Active Trials
NCT06471036Recruiting400Est. Feb 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Daewon PharmaCombination therapy
SandozInclisiran Sodium
AmgenCare Champion Intervention

Clinical Trials (3)

Total enrollment: 5,675 patients across 3 trials

NCT06767774Daewon PharmaCombination therapy

Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus

Start: Apr 2025Est. completion: Jan 20302,000 patients
Phase 4Recruiting
NCT03814187SandozInclisiran Sodium

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

Start: Apr 2019Est. completion: Feb 20233,275 patients
Phase 3Completed
NCT06471036AmgenCare Champion Intervention

Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?

Start: Oct 2024Est. completion: Feb 2027400 patients
N/ARecruiting

Related Jobs

Senior Director, Clinical Research, Atherosclerosis

Merck & Co.Merck & Co.
USA - New Jersey - Rahway; USA - Massachusetts - Boston (MA Parcel B Laboratory) (Hybrid)
1w ago
$277K - $435K/yr

Senior Director, Clinical Research, Atherosclerosis

Verona PharmaVerona Pharma
USA - New Jersey - Rahway; USA - Massachusetts - Boston (MA Parcel B Laboratory) (Hybrid)
1w ago
$277K - $435K/yr

Director, Product Strategy Lead, ASCVD

NovartisNovartis
East Hanover
4w ago
$186K - $345K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 5,675 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.